Article Text

Download PDFPDF
329 The significance of detecting hypermethylation levels of CDO1 and HOXA9 in serum for early diagnosis of ovarian cancer
  1. Lei Li1,
  2. Xiaopei Chao1,
  3. Linghua Kong1,
  4. Lin Han2,
  5. Suiqiong Lin2,
  6. Hsiangyu Chuang2,
  7. Xiangyu Zhuang2 and
  8. Pei Liu2
  1. 1Department of Obstetrics and Gynecology, National Clinical Research Center for Obstetric and Gynecologic Diseases, Peking Union Medical College Hospital, Beijing, China
  2. 2Beijing Origin Poly Bio-Tec Co., Ltd., Beijing, China


Introduction/Background Efforts to enhance the non-invasive detection of ovarian cancer (OC) are imperative, given the substantial improvement in survival rates associated with early diagnosis and treatment. This study aims to explore the clinical value of detecting hypermethylation levels of CDO1 and HOXA9 in serum for the early diagnosis of OC.

Methodology A prospective study involving 141 patients undergoing surgery at Peking Union Medical College Hospital from May 2020 to April 2022 was conducted. Blood samples were collected preoperatively for CA125 level evaluation and DNA methylation testing. Simultaneously, comprehensive clinical information, biomarkers and transvaginal ultrasound (TVS) data were recorded. The clinical efficacy of DNA methylation detection for OC was assessed using the CISOVA methylation (CDO1 and HOXA9) real-time system (Beijing OriginPoly Bio-Tec Co., China) as a representative model.

Results Analysis of 90 ovarian cancers and 51 benign-masses confirmed by pathology revealed that age, menopausal status, CA125 levels and hypermethylation levels of CDO1 and HOXA9, either singly or in combination, were significantly higher in OC patients compared to the benign group (P<0.05). Notably, among these detection protocols, the CISOVA (CDO1 and HOXA9) dual gene methylation exhibited a sensitivity of 87.8% and a specificity of 90.2%. The positive detection rate for early OC (FOGO stage I-II) using CISOVA was 80.0% higher than that of CA125 testing.

Conclusion Blood cell-free DNA methylation detection emerges as a promising and non-invasive method with highly sensitivity and specificity for OC diagnosis, outperforming current testing modalities for high-risk individuals. This approach holds the potential to significantly reduce invasive procedures, alleviate psychological burdens and surgical risks for patients, and improves compliance throughout the detection process.

Disclosures Conflict of Interest Disclosure Statement

The European Society of Gynaecological Oncology requires clear disclosures from all presenters at its annual congress regarding any financial holdings, funding sources, or affiliations that might raise questions of bias or be perceived to have potentially influenced presentation content.

Please disclose any financial relationship from the past three years (dating from the month of submission) of any size.

NAME: Lei Li

AFFILIATION: Department of Obstetrics and Gynecology,National Clinical Research Center for Obstetric & Gynecologic Diseases,State Key Laboratory for Complex, Severe and Rare Diseases, Peking Union Medical College Hospital

I have no potential conflict of interest to report

Signature: Lei Li Date: November 13th

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.